Lipella Pharmaceuticals Inc Ordinary Shares LIPO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LIPO is a good fit for your portfolio.
News
-
Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus
-
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
-
Lipella Gets FDA Orphan Designation for LP-310 in Oral Graft-vs-Host Disease
Trading Information
- Previous Close Price
- $0.40
- Day Range
- $0.39–0.43
- 52-Week Range
- $0.36–2.71
- Bid/Ask
- $0.40 / $0.42
- Market Cap
- $3.07 Mil
- Volume/Avg
- 51,214 / 45,085
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.74
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 7
- Website
- https://www.lipella.com
Valuation
|
Metric
|
LIPO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.11 |
Price/Sales | 5.74 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LIPO
|
|---|---|
Quick Ratio | 3.94 |
Current Ratio | 5.46 |
Interest Coverage | −894.60 |
Quick Ratio
LIPO
Profitability
|
Metric
|
LIPO
|
|---|---|
Return on Assets (Normalized) | −95.92% |
Return on Equity (Normalized) | −113.92% |
Return on Invested Capital (Normalized) | −111.55% |
Return on Assets
LIPO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Jxsdmchhd | Kddlc | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xqklxzgl | Wwmkgf | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Whjftwkh | Gwxwjs | $118.7 Bil | |||
| Moderna Inc
MRNA
| Vxwjjfmf | Xjss | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wqjwzgx | Shwmc | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Lbktybwdy | Jgbc | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Fltvjymnv | Jph | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Btkdntdk | Ykdxxx | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Rmtyjczy | Ggyy | $15.0 Bil | |||
| Incyte Corp
INCY
| Dqmrghn | Pshyr | $13.5 Bil |